Q-omics provides the consensus-scored WBP1L profile across patient tissues and cancer cell-line models. WBP1L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, WBP1L is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, WBP1L RNA expression shows 19,730 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRC, and ACC as cancer lineages where WBP1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WBP1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WBP1L survival associations across molecular data types. WBP1L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WBP1L RNA expression–survival associations across cancer types. High WBP1L expression shows unfavorable associations in UVM, ACC and BLCA, but favorable associations in UCS, MESO and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for WBP1L RNA expression.
This table summarizes WBP1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for WBP1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WBP1L shows lower tumor expression in THCA, COAD, UCEC and LUSC and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher WBP1L RNA expression in tumor versus normal tissue (log2 FC = +0.530, t-test p < 0.001).
This table shows molecular features associated with WBP1L in patient tissues and cancer cell lines. In patient samples, WBP1L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WBP1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
